Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Sponsor: Mansoura University
Summary
Preclinical data indicate that rifaximin could be repurposed as a novel strategy for preventing and reducing the severity of gastrointestinal damage, particularly diarrhea, that results from pelvic irradiation. So, The aim of the work is to investigate the impact of Rifaximin on the incidence and severity of radiotherapy-induced diarrhea in cancer patients undergoing pelvic irradiation with or without chemotherapy.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-01-20
Completion Date
2025-12
Last Updated
2025-01-20
Healthy Volunteers
No
Conditions
Interventions
Rifaximin 550 MG
Oral Rifaximin 550mg twice daily from the start of pelvic radiotherapy, with or without chemotherapy, as a preventive measure, and continuing every day until the end of the treatment up to 5 to seven weeks.
Standard Care Chemoradiation
Patients will receive standard chemotherapy and/or radiation
Locations (1)
Mansoura University
Al Mansurah, Province, Egypt